MedPath

Yuyu Pharma, Inc.

Yuyu Pharma, Inc. logo
🇰🇷South Korea
Ownership
Public
Established
1941-02-28
Employees
259
Market Cap
-
Website
http://www.yuyu.co.kr

Clinical Trials

7

Active:0
Completed:7

Trial Phases

3 Phases

Phase 1:3
Phase 2:2
Phase 3:2

Drug Approvals

1

PHILIPPINES:1

Drug Approvals

Cholergol

Approval Date
Jul 14, 2025
PHILIPPINES

Clinical Trials

Distribution across different clinical trial phases (7 trials with phase data)• Click on a phase to view related trials

Phase 1
3 (42.9%)
Phase 2
2 (28.6%)
Phase 3
2 (28.6%)

Phase 2, Multi-center, Randomized, Double- Masked and Placebo-Controlled Study of YP-P10 Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye (ICECAP 1)

Phase 2
Completed
Conditions
Dry Eye
Interventions
Drug: 0.3% YP-P10 Ophthalmic Solution
Drug: 1% YP-P10 Ophthalmic Solution
Drug: YP-P10 Placebo Ophthalmic Solution (vehicle)
First Posted Date
2022-07-20
Last Posted Date
2024-07-30
Lead Sponsor
Yuyu Pharma, Inc.
Target Recruit Count
257
Registration Number
NCT05467293
Locations
🇺🇸

Cornea Consultants of Arizona, Phoenix, Arizona, United States

🇺🇸

Aesthetic Eye Care Institute, Newport Beach, California, United States

🇺🇸

Vision Institute, Colorado Springs, Colorado, United States

and more 4 locations

Pharmacokinetics and Safety/Tolerability of YY-201 in Comparison to Dutasteride and Tadalafil

Phase 1
Completed
Conditions
Benign Prostatic Hyperplasia
Interventions
First Posted Date
2017-08-07
Last Posted Date
2017-11-24
Lead Sponsor
Yuyu Pharma, Inc.
Target Recruit Count
36
Registration Number
NCT03240939
Locations
🇰🇷

Asan Medical Center, Seoul, Korea, Republic of

A Study to Investigate the Pharmacokinetic Drug Interactions Between Dutasteride and Tadalafil in Healthy Male Subjects

Phase 1
Completed
Conditions
Benign Prostate Hyperplasia
Interventions
First Posted Date
2016-07-20
Last Posted Date
2017-04-04
Lead Sponsor
Yuyu Pharma, Inc.
Target Recruit Count
28
Registration Number
NCT02839122

Efficacy and Safety Study of Combination of Ginkgo Extract and Ginseng Extract in Children With ADHD(Attention Deficit Hyperactivity Disorder)

Phase 3
Completed
Conditions
Mental Disorders
Interventions
Drug: Placebo
First Posted Date
2012-02-20
Last Posted Date
2019-02-25
Lead Sponsor
Yuyu Pharma, Inc.
Target Recruit Count
144
Registration Number
NCT01536210
Locations
🇰🇷

Hallym University Hospital, Anyang-si, Korea, Republic of

🇰🇷

Inje University Ilsan Paik Hospital, Goyang-Si, Korea, Republic of

🇰🇷

Seoul National University Hospital, Seoul, Korea, Republic of

Pharmacokinetics of Maxmarvil® in Healthy Postmenopausal Women

Phase 1
Completed
Conditions
Osteoporosis
Interventions
Drug: Maxmarvil®
First Posted Date
2012-02-03
Last Posted Date
2019-02-25
Lead Sponsor
Yuyu Pharma, Inc.
Target Recruit Count
18
Registration Number
NCT01526278
Locations
🇰🇷

Ajou University Hospital, Suwon, Korea, Republic of

  • Prev
  • 1
  • 2
  • Next

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.